Literature DB >> 17945291

Desmopressin resistant nocturnal polyuria may benefit from furosemide therapy administered in the morning.

A De Guchtenaere1, C Vande Walle, P Van Sintjan, R Donckerwolcke, A Raes, J Dehoorne, E Van Laecke, P Hoebeke, J Vande Walle.   

Abstract

PURPOSE: There is increasing evidence that a subgroup of patients with monosymptomatic nocturnal enuresis and nocturnal polyuria resistant to desmopressin may have an abnormal circadian rhythm of renal tubular sodium handling. The pathogenesis of this phenomenon remains to be elucidated. If the increased sodium excretion overnight results in desmopressin resistance, decreasing the sodium excretion overnight may result in subsequently better desmopressin response.
MATERIALS AND METHODS: We conducted a pilot study of the anti-enuretic and antidiuretic effects of desmopressin combined with 0.5 mg/kg furosemide daily in patients with desmopressin resistant nocturnal polyuria despite dietary sodium and protein restriction. Values were plotted against the reference frame of a desmopressin responsive enuresis group.
RESULTS: Baseline values revealed significantly lower urinary osmolality and higher diuresis rate overnight compared to the reference population (monosymptomatic nocturnal enuresis desmopressin responders). Introduction of desmopressin resulted in normalization of nocturnal urinary osmolality. However, nocturnal polyuria persisted, despite reaching maximal urinary concentration overnight. Although protein and sodium restriction resulted in a significant decrease in urinary osmolality and diuresis rate, the difference was not clinically important enough to reach normal values or to achieve continence. Furosemide in the morning resulted in a significant increase in diuresis and osmotic and sodium excretion during the day, and decreased nighttime diuresis and osmotic excretion. In 9 of 12 patients the nocturnal antidiuretic effect resulted in an anti-enuretic effect, defined as enuresis less than 1 wet night per month. In 3 patients insufficient anti-enuretic effects were obtained despite significant antidiuresis.
CONCLUSIONS: This pilot study clearly demonstrates that introduction of early morning furosemide results in a significantly lower nocturnal diuresis rate. Reduced diuresis associated with unchanged urinary osmolality results in decreased nocturnal osmotic excretion in compensation for increased osmotic (sodium) excretion during the daytime.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17945291     DOI: 10.1016/j.juro.2007.08.026

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Renal bladder ultrasound evaluation in monosymptomatic primary nocturnal enuresis: is it really necessary?

Authors:  Larisa Kovacevic; Cortney Wolfe-Christensen; Jelena Mirkovic; Jessica Yih; Yegappan Lakshmanan
Journal:  Pediatr Nephrol       Date:  2014-01-18       Impact factor: 3.714

Review 2.  The pathophysiology of monosymptomatic nocturnal enuresis with special emphasis on the circadian rhythm of renal physiology.

Authors:  L Dossche; J Vande Walle; C Van Herzeele
Journal:  Eur J Pediatr       Date:  2016-05-02       Impact factor: 3.183

3.  Circadian rhythms in urinary functions: possible roles of circadian clocks?

Authors:  Jong-Yun Noh; Dong-Hee Han; Ji-Ae Yoon; Mi-Hee Kim; Sung-Eun Kim; Il-Gyu Ko; Khae-Hawn Kim; Chang-Ju Kim; Sehyung Cho
Journal:  Int Neurourol J       Date:  2011-06-30       Impact factor: 2.835

Review 4.  Brazilian consensus in enuresis-recomendations for clinical practice.

Authors:  José Murillo Bastos; Atila Victal Rondon; George Rafael Martins de Lima; Miguel Zerati; Edison Daniel Schneider-Monteiro; Carlos Augusto F Molina; Adriano de Almeida Calado; Ubirajara Barroso
Journal:  Int Braz J Urol       Date:  2019 Sep-Oct       Impact factor: 3.050

Review 5.  Optimizing response to desmopressin in patients with monosymptomatic nocturnal enuresis.

Authors:  Konstantinos Kamperis; Charlotte Van Herzeele; Soren Rittig; Johan Vande Walle
Journal:  Pediatr Nephrol       Date:  2016-04-12       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.